🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 17 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/03/2024 58,63 58,63 56,44 56,52 -2,84% 3,74% 1.117.100
15/03/2024 59,78 60,54 57,80 58,17 -2,77% 4,58% 1.485.700
14/03/2024 59,97 60,29 59,11 59,83 +0,25% 1,97% 709.500
13/03/2024 60,48 61,28 59,52 59,68 -1,97% 2,91% 646.400
12/03/2024 62,75 62,97 60,82 60,88 -2,93% 3,42% 641.600
11/03/2024 62,51 63,25 61,25 62,72 +0,32% 3,20% 816.000
08/03/2024 63,03 65,40 62,43 62,52 -0,11% 4,71% 1.036.500
07/03/2024 61,96 63,11 61,41 62,59 +1,00% 2,74% 840.300
06/03/2024 64,89 65,24 61,86 61,97 -3,83% 5,21% 1.202.200
05/03/2024 65,23 65,90 63,85 64,44 -1,41% 3,14% 578.400
04/03/2024 65,00 66,23 64,09 65,36 +1,11% 3,28% 904.400
01/03/2024 65,55 66,42 64,30 64,64 -1,13% 3,23% 707.000
29/02/2024 66,31 66,81 64,42 65,38 +0,02% 3,60% 680.900
28/02/2024 67,85 67,85 64,93 65,37 -4,23% 4,30% 963.900
27/02/2024 68,49 69,73 67,80 68,26 +0,18% 2,82% 1.103.000
26/02/2024 66,20 69,16 65,81 68,14 +2,82% 5,06% 1.377.200
23/02/2024 65,27 66,60 65,00 66,27 +1,88% 2,45% 1.232.700
22/02/2024 63,00 65,59 61,70 65,05 +14,71% 6,17% 2.547.500
21/02/2024 56,19 57,47 56,06 56,71 -0,21% 2,51% 1.255.200
20/02/2024 57,00 57,84 56,54 56,83 -1,10% 2,29% 900.800
16/02/2024 57,18 58,24 56,40 57,46 -0,50% 3,22% 688.700
15/02/2024 56,81 58,19 56,51 57,75 +2,45% 2,96% 798.600
14/02/2024 55,69 56,61 55,01 56,37 +2,70% 2,87% 596.400
13/02/2024 55,31 56,06 54,69 54,89 -2,94% 2,48% 755.700
12/02/2024 56,59 56,90 55,41 56,55 +0,73% 2,63% 794.400
09/02/2024 56,00 56,36 55,48 56,14 +1,04% 1,57% 665.700
08/02/2024 54,38 55,90 53,47 55,56 +1,76% 4,48% 618.100
07/02/2024 55,31 55,64 54,56 54,60 -0,71% 1,94% 661.300
06/02/2024 54,26 55,39 53,86 54,99 +1,72% 2,81% 716.200
05/02/2024 53,63 54,24 52,96 54,06 +0,11% 2,39% 662.900